Mrs Katherine A Gee Champagne, LICSW | |
2843 South County Trail C 8, East Greenwhich, RI 02818 | |
(401) 486-7728 | |
Not Available |
Full Name | Mrs Katherine A Gee Champagne |
---|---|
Gender | Female |
Speciality | Social Worker - Clinical |
Location | 2843 South County Trail C 8, East Greenwhich, Rhode Island |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1457423444 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | ISW01402 (Rhode Island) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Katherine A Gee Champagne, LICSW 22 Wood Rd, Richmond, RI 02898 Ph: (401) 539-0531 | Mrs Katherine A Gee Champagne, LICSW 2843 South County Trail C 8, East Greenwhich, RI 02818 Ph: (401) 486-7728 |
News Archive
Green Cross Corporation, a South Korean biopharmaceutical company, announced today that South Korea's Ministry of Food and Drug Safety has approved GCFLU QUADRIVALENT (Influenza Virus Vaccine) for immunisation of adults to help prevent disease caused by seasonal influenza (flu) virus subtype A and B. GCFlu Quadrivalent is the first locally-manufactured vaccine to cover against four influenza strains.
To keep reporters up to date with the latest developments on the age beat, The Gerontological Society of America (GSA) is proud to host a series of press briefings and a journalists' networking reception at its upcoming Annual Scientific Meeting in Atlanta, GA. The program schedule additionally offers over 400 other scientific sessions featuring research presented for the first time.
With nearly half of the world's population at risk for life-threatening malaria infections, University of Maryland School of Medicine (UMSOM) researchers and their colleagues identified an important public health measure to control the disease.
Protalix BioTherapeutics, Inc., announced today that it received notification from the U.S. Food and Drug Administration (FDA) that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date of the New Drug Application (NDA) for taliglucerase alfa to May 1, 2012, a three-month extension from the previous PDUFA date of February 1, 2012.
› Verified 5 days ago